Visione elleniche / Eugenio della Valle

• Record Nr.: UNINA990007009140403321
• Autore: Della Valle, Eugenio
• Pubbl/distr/stampa: Bari : Laterza, 1960
• Descrizione fisica: 110 p. ; 18 cm
• Locazione: BAT
• Collocazione: BIB. BAT.5387
• Lingua di pubblicazione: Italiano
• Formato: Materiale a stampa
• Livello bibliografico: Monografia

Multiple sclerosis : a guide to pharmacologic treatment / / D. Ontaneda

• Record Nr.: UNINA9910464794103321
• Autore: Ontaneda D.
• Pubbl/distr/stampa: Torino, Italy : , : SEEd, , 2013
• ISBN: 88-97419-48-8
• Edizione: [First edition.]
• Descrizione fisica: 1 online resource (150 p.)
• Soggetti: Multiple sclerosis - Treatment; Pharmacology; Electronic books.
• Lingua di pubblicazione: Inglese
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Note generali: Description based upon print version of record.
• Nota di bibliografia: Includes bibliographical references.
• Nota di contenuto: ""Title Page""; ""Colophon""; ""Table of Contents""; ""Section I. Introduction""; ""Scope""; ""New Therapies and Risks""; ""Overview of Multiple Sclerosis""; ""Basic pathogenesis""; ""Disease forms""; ""Approach to treatment""; ""Goals of treatment""; ""Challenges""; ""References""; ""Section II. Disease Modifying Agents for Multiple Sclerosis""; ""Interferon for MS""; ""Introduction""; ""Mechanism of ; Action""; ""Efficacy""; ""Safety and Risks""; ""Conclusions""; ""References""; ""Glatiramer acetate for MS""; ""Introduction""; ""Mechanism of Action""; ""Efficacy""; ""Safety and Risks""; ""Conclusions""""References""; ""Mitoxantrone for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusions""; ""References""; ""Natalizumab for MS""; ""Introduction""; ""Mechanism of Action""; ""Efficacy""; ""Safety and Risks""; ""Conclusions""; ""References""; ""Fingolimod for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusions""; ""References""; ""Teriflunomide for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusion""; ""References""; ""Dimethyl fumarate for MS""""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusions""; ""References""; ""Section III. Treatment of relapses""; ""Defining Relapses""; ""Introduction""; ""Relapse symptoms""; ""MRI in MS Relapses""; ""Natural History of MS Relapses""; ""References""; ""Treatment of MS relapses""; ""Introduction""; ""Corticosteroids (CS) and ACTH""; ""Plasma exchange""; ""IVIG""; ""References""; ""Section IV. Emerging therapies for multiple sclerosis""; ""Laquinimod for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""""Conclusions""; ""References""; ""Alemtuzumab for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusions""; ""References""; ""Daclizumab for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusions""; ""References""; ""Ocrelizumab and Rituximab for MS""; ""Introduction""; ""Mechanism of action""; ""Efficacy""; ""Safety and risks""; ""Conclusions""; ""References""; ""Author""